文章核心观点 - 公司第二季度核心Illumina收入为10.92亿美元,同比下降6%,环比增长3% [1][2][3] - 公司第二季度核心Illumina GAAP营业利润率为40.5%,非GAAP营业利润率为22.2% [9] - 公司预计2024财年核心Illumina收入将下降2%至3%,非GAAP营业利润率将提升至20.5%至21% [14] 核心Illumina业务 - 第二季度核心Illumina收入同比下降6%,主要受到客户资金环境紧缩导致仪器需求疲软的影响 [3][10] - 第二季度核心Illumina毛利率同比提升,主要得益于产品组合更有利以及运营效率提升 [10] - 第二季度核心Illumina研发费用和销售费用同比有所下降 [8][9] GRAIL业务 - 第二季度GRAIL收入为2900万美元,毛利为1500万美元 [11] - 第二季度GRAIL研发费用和销售费用分别为8800万美元和8400万美元 [11] - 公司在第二季度确认了14.66亿美元的商誉减值和4.2亿美元的无形资产减值 [5][11] 其他动态 - 公司于6月24日完成了GRAIL的分拆上市 [1][13] - 公司收购了Fluent Biosciences,并任命Everett Cunningham为首席商务官 [13] - 公司在ASCO年会上发表了14篇研究成果,并推出了多项新产品和技术 [13]

The upcoming report from Illumina (ILMN) is expected to reveal quarterly earnings of $0.23 per share, indicating a decline of 28.1% compared to the year-ago period. Analysts forecast revenues of $1.1 billion, representing a decrease of 6.7% year over year.The current level reflects an upward revision of 54.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Ahead ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Illumina (ILMN) , which belongs to the Zacks Medical - Biomedical and Genetics industry.This genetic testing tools company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 750%.For the last reported quarter, Illumina came out with earnings of $0.09 per ...

Shares of Illumina (ILMN) have gained 5.5% over the past four weeks to close the last trading session at $114.49, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $145.43 indicates a potential upside of 27%.The mean estimate comprises 21 short-term price targets with a standard deviation of $36.38. While the lowest estimate of $100 indicates a 12.7% decline from the current price ...

SAN DIEGO, July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am Pacific Time. The event will feature presentations by members of Illumina's executive team and conclude with a Q&A session.Webcast DetailsThe webcast can be accessed through the Events & Presentations section of Illumina's Investor Relations website at investor.illumina.com. We recommend that participants pre-regi ...

Illumina (ILMN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a c ...

Illumina TodayILMNIllumina$116.56 +0.47 (+0.40%) 52-Week Range$89.00▼$195.64Price Target$158.57Add to WatchlistLife sciences company Illumina Inc. NASDAQ: ILMN stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of GRAIL, LLC NASDAQ: GRAL on June 24, 2024. Illumina had previously acquired the early detection cancer testing company for $8 billion in 2021.Get Illumina alerts:Illumina's GRAIL Acquisition Backfired, Resulting i ...

INDIA - 2023/12/16: In this photo illustration, the Illumina logo is seen displayed on a mobile ... [+] phone screen. (Photo Illustration by Idrees Abbas/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIllumina stock (NASDAQ: ILMN) saw a 6% rise on Wednesday, July 10, faring better than its peer — Mettler-Toledo stock – up 1%. The rise in ILMN stock can primarily be attributed to the company’s acquisition of Fluent Biosciences to expand its single-cell analysis and multiomic ...

SAN DIEGO, July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of market on Tuesday, August 6, 2024. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Cal ...

Loading...Loading...Wednesday, Illumina Inc ILMN acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration.Amid this M&A deal, 10x Genomics, Inc TXG shares are trading lower.William Blair writes that Fluent’s PIPseq single-cell technology does not require an instrument, and costs per cell is at least 50% less than 10x and is the cheapest on the market, citing a recent bioRxiv preprint.William Blair highlights that cost reduction has beco ...